A Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Effects of Subcutaneously Administered REGN3500 in Adult Patients With Moderate Asthma
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Itepekimab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 19 Dec 2018 New trial record